Plant Services


For decades, regulatory bodies like the FDA have created a culture of risk aversion. In response, pharma and medical product companies have designed maintenance programs that over-inspect and over-spend on equipment. Profit margins may allow for it, but there are significant downsides to this strategy, including safety risks, negative ESG impacts, avoidable costs, and low asset utilization.

To understand the full impact of delaying the evolution of predictive maintenance, we had Zach Gilula, Pharma Machine Health Lead at Augury and David Seignolle, former VP, Head of Operations at Teva, discussing how pharma and medical product companies can overcome their outdated cautiousness to:

  • Cut maintenance costs and deviation incidents
  • Reduce third-party dependencies
  • Gain greater control over your their manufacturing environments

Reducing planned outages means either debottlenecking the process or reducing the number of tasks to shorten the duration, and the only way to do that is with condition-based programs, which most respondents say they don’t have.


Meet the Speakers

Zach Gilula headshot.jpeg

Zach Gilula

Pharma Machine Health Lead at Augury

David Seignolle headshot.jpeg

David Seignolle

Former VP, Head of Operations at Teva

Access this additional resource when you register:

Preview the findings

Download this infographic to get an overview of the issues confronting plant services.

Across Indus